Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
K Ghoreschi, A Balato, C Enerbäck, R Sabat - The Lancet, 2021 - thelancet.com
Psoriasis is a chronic inflammatory disease characterised by sharply demarcated
erythematous and scaly skin lesions accompanied by systemic manifestations. Classified by …
erythematous and scaly skin lesions accompanied by systemic manifestations. Classified by …
Anti-IL17 therapies for psoriasis
A Silfvast-Kaiser, SY Paek, A Menter - Expert Opinion on Biological …, 2019 - Taylor & Francis
ABSTRACT Introduction: Interleukin-17 (IL-17) is a proinflammatory cytokine considered to
play a significant role in the immunopathogenesis of plaque psoriasis. As a result, focus in …
play a significant role in the immunopathogenesis of plaque psoriasis. As a result, focus in …
The role of IL 23 in the treatment of psoriasis
L Puig - Expert review of clinical immunology, 2017 - Taylor & Francis
ABSTRACT Introduction: The IL-23/IL-17 axis is currently considered to be crucial in the
pathogenesis of psoriasis. Human IL-23 is primarily produced by antigen-presenting cells …
pathogenesis of psoriasis. Human IL-23 is primarily produced by antigen-presenting cells …
Clinical improvement in psoriasis with specific targeting of interleukin-23
T Kopp, E Riedl, C Bangert, EP Bowman… - Nature, 2015 - nature.com
Psoriasis is a chronic inflammatory skin disorder that affects approximately 2–3% of the
population worldwide and has severe effects on patients' physical and psychological well …
population worldwide and has severe effects on patients' physical and psychological well …
Anti IL-17 in psoriasis
K Ly, MP Smith, Q Thibodeaux, V Reddy… - Expert review of …, 2019 - Taylor & Francis
Introduction: Psoriasis is a chronic, immune-mediated disease with significant associated
comorbidities. Its pathogenesis is likely multifactorial, however, the interleukin-23/T helper …
comorbidities. Its pathogenesis is likely multifactorial, however, the interleukin-23/T helper …
Major role of the IL17/23 axis in psoriasis supports the development of new targeted therapies
H Bugaut, S Aractingi - Frontiers in Immunology, 2021 - frontiersin.org
Psoriasis is a frequent, chronic disease characterized by cutaneous inflammatory plaques
and/or arthritis. It may be associated with few other diseases, mainly Crohn's disease and …
and/or arthritis. It may be associated with few other diseases, mainly Crohn's disease and …
Psoriasis
Psoriasis is a common, chronic papulosquamous skin disease occurring worldwide,
presenting at any age, and leading to a substantial burden for individuals and society. It is …
presenting at any age, and leading to a substantial burden for individuals and society. It is …
Cytokine-based therapy in psoriasis
Psoriasis and psoriatic arthritis are chronic inflammatory diseases of unknown etiology,
affecting 2–3% of the world population. Initially, psoriasis was thought to be a hyper …
affecting 2–3% of the world population. Initially, psoriasis was thought to be a hyper …
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
PJ Mease, P Rahman, AB Gottlieb, AP Kollmeier… - The Lancet, 2020 - thelancet.com
Summary Background The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in
psoriatic arthritis pathogenesis. Guselkumab, an IL-23 inhibitor that specifically binds the IL …
psoriatic arthritis pathogenesis. Guselkumab, an IL-23 inhibitor that specifically binds the IL …
Targeting the IL-17-TH17 pathway.
HS Bartlett, RP Million - Nature Reviews Drug Discovery, 2015 - nature.com
Targeting pro-inflammatory cytokines such as tumour necrosis factor-α (TNF-α) has been an
effective therapeutic approach in patients with a variety of autoimmune diseases, including …
effective therapeutic approach in patients with a variety of autoimmune diseases, including …